KYT

Kyverna

Stock
Stock
Ticker: KYTX
KYTX

Price

Price

CHART BY

Frequently asked questions

What is Kyverna's market capitalization?

The market capitalization of Kyverna is $517.98M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Kyverna?

Kyverna's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$3.28. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Kyverna's stock?

Currently, 6 analysts cover Kyverna's stock, with a consensus target price of $30.40. Analyst ratings provide insights into the stock's expected performance.

What is the EBITDA for Kyverna?

Kyverna's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$162.14M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Kyverna?

Kyverna has a free cash flow of -$151.53M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

How many employees does Kyverna have, and what sector and industry does it belong to?

Kyverna employs approximately 130 people. It operates in the Health Care sector, specifically within the Biotechnology industry.

What is the free float of Kyverna's shares?

The free float of Kyverna is 37.73M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$517.98M
EPS (TTM) 
-$3.28
Free Float 
37.73M
EBITDA (TTM) 
-$162.14M
Free Cashflow (TTM) 
-$151.53M

Pricing

52W span
$2.52$13.64

Analyst Ratings

The price target is $30.40 and the stock is covered by 6 analysts.

Buy

6

Hold

0

Sell

0

Information

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Employees
130
Industries
Biotechnology
Sector
Health Care

Identifier

Primary Ticker
KYTX
Fundamentals & EOD data from FactSet
Join the conversation